Puma Biotechnology Inc. (NYSE:PBYI) has been given a $88.00 target price by stock analysts at Citigroup Inc. in a research note issued on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective would suggest a potential upside of 104.41% from the stock’s previous close.

Several other equities analysts have also recently issued reports on PBYI. Stifel Nicolaus restated a “buy” rating and issued a $88.00 price target on shares of Puma Biotechnology in a research report on Thursday, November 10th. JPMorgan Chase & Co. set a $89.00 price target on Puma Biotechnology and gave the company a “buy” rating in a research report on Tuesday, September 20th. Credit Suisse Group AG boosted their price target on Puma Biotechnology from $54.00 to $111.00 and gave the company an “outperform” rating in a research report on Thursday, September 22nd. Vetr cut Puma Biotechnology from a “strong-buy” rating to a “strong sell” rating and set a $39.50 price target on the stock. in a research report on Wednesday, August 10th. Finally, RBC Capital Markets restated a “sector perform” rating on shares of Puma Biotechnology in a research report on Thursday, September 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. Puma Biotechnology has a consensus rating of “Buy” and a consensus target price of $68.56.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology (NYSE:PBYI) opened at 43.05 on Monday. The stock’s market cap is $1.59 billion. The firm’s 50-day moving average price is $50.13 and its 200-day moving average price is $43.94. Puma Biotechnology has a 12 month low of $19.74 and a 12 month high of $82.81.

A number of institutional investors have recently added to or reduced their stakes in PBYI. BNP Paribas Arbitrage SA boosted its stake in Puma Biotechnology by 112.0% in the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 1,127 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Puma Biotechnology by 184.3% in the first quarter. JPMorgan Chase & Co. now owns 176,530 shares of the biopharmaceutical company’s stock worth $5,185,000 after buying an additional 114,428 shares in the last quarter. Northern Capital Management LLC boosted its stake in Puma Biotechnology by 1.2% in the second quarter. Northern Capital Management LLC now owns 16,288 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 190 shares in the last quarter. Traynor Capital Management Inc. purchased a new stake in Puma Biotechnology during the second quarter worth $246,000. Finally, Iguana Healthcare Management LLC boosted its stake in Puma Biotechnology by 16.3% in the first quarter. Iguana Healthcare Management LLC now owns 29,070 shares of the biopharmaceutical company’s stock worth $854,000 after buying an additional 4,070 shares in the last quarter. Institutional investors own 87.54% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Stock Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related stocks with our FREE daily email newsletter.